Evofem Biosciences, Inc. (EVFM) › Shareholders' EquityEvofem Biosciences, Inc. (EVFM) — Shareholders' EquityAnnual figures by period end, from SEC filings.2012-12-31: -$41.76M2013-12-31: -$56.69M2014-12-31: $65.25M2015-12-31: $23.81M2016-12-31: -$181.09M2017-12-31: -$289.55M2018-12-31: -$23.36M2019-12-31: $15.64M2020-12-31: $1.35M2021-12-31: -$104.31M2022-12-31: -$71.80M2023-12-31: -$66.51M2024-12-31: -$71.26M2025-12-31: -$74.34M-$74.34M2012-12-31Shareholders' Equity (USD)2025-12-31Period endedShareholders' EquityChange YoYSource filing2025-12-31-$74.34M—2026-03-11Balance as of period end2024-12-31-$71.26M—2026-03-11Balance as of period end2023-12-31-$66.51M—2026-03-11Balance as of period end2022-12-31-$71.80M—2025-03-24Balance as of period end2021-12-31-$104.31M-7844.2%2024-03-27Balance as of period end2020-12-31$1.35M-91.4%2023-04-27Balance as of period end2019-12-31$15.64M—2022-03-10Balance as of period end2018-12-31-$23.36M—2021-03-04Balance as of period end2017-12-31-$289.55M—2020-03-12Balance as of period end2016-12-31-$181.09M-860.6%2019-03-01Balance as of period end2015-12-31$23.81M-63.5%2018-02-26Balance as of period end2014-12-31$65.25M—2018-02-26Balance as of period end2013-12-31-$56.69M—2017-03-23Balance as of period end2012-12-31-$41.76M—2016-03-29Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)